News | August 06, 2021
Strides to acquire US manufacturing facility of Endo for $24 mn
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Bayer expects 2025 to be the most difficult year of its turnaround
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated
